ES2961390T3 - Montelukast para el tratamiento de la osteoartritis erosiva de la mano - Google Patents
Montelukast para el tratamiento de la osteoartritis erosiva de la mano Download PDFInfo
- Publication number
- ES2961390T3 ES2961390T3 ES19805716T ES19805716T ES2961390T3 ES 2961390 T3 ES2961390 T3 ES 2961390T3 ES 19805716 T ES19805716 T ES 19805716T ES 19805716 T ES19805716 T ES 19805716T ES 2961390 T3 ES2961390 T3 ES 2961390T3
- Authority
- ES
- Spain
- Prior art keywords
- montelukast
- pharmaceutically acceptable
- acceptable salt
- day
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382851 | 2018-11-26 | ||
| PCT/EP2019/082425 WO2020109230A1 (en) | 2018-11-26 | 2019-11-25 | Montelukast for the treatment of erosive hand osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2961390T3 true ES2961390T3 (es) | 2024-03-11 |
Family
ID=64665075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19805716T Active ES2961390T3 (es) | 2018-11-26 | 2019-11-25 | Montelukast para el tratamiento de la osteoartritis erosiva de la mano |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12539296B2 (enExample) |
| EP (1) | EP3886857B1 (enExample) |
| JP (1) | JP7399502B2 (enExample) |
| CN (1) | CN113347975B (enExample) |
| AU (1) | AU2019386235B2 (enExample) |
| BR (1) | BR112021009980A2 (enExample) |
| CA (1) | CA3120920C (enExample) |
| DK (1) | DK3886857T3 (enExample) |
| ES (1) | ES2961390T3 (enExample) |
| FI (1) | FI3886857T3 (enExample) |
| HR (1) | HRP20231283T1 (enExample) |
| HU (1) | HUE063579T2 (enExample) |
| MA (1) | MA54276B1 (enExample) |
| MD (1) | MD3886857T2 (enExample) |
| MX (1) | MX2021006209A (enExample) |
| MY (1) | MY203365A (enExample) |
| PL (1) | PL3886857T3 (enExample) |
| PT (1) | PT3886857T (enExample) |
| RS (1) | RS64668B1 (enExample) |
| SI (1) | SI3886857T1 (enExample) |
| TW (1) | TWI850283B (enExample) |
| WO (1) | WO2020109230A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230372324A1 (en) * | 2020-10-13 | 2023-11-23 | Diomed Developments Ltd. | Gel formulations comprising montelukast |
| GB2599912B (en) * | 2020-10-13 | 2023-04-19 | Diomed Dev Ltd | New formulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201020085D0 (en) * | 2010-11-26 | 2011-01-12 | Xaragen Pharma Ltd | Methods and reagents for the treatment of arthritic disorders |
| TW201536320A (zh) | 2013-12-02 | 2015-10-01 | Abbvie Inc | 治療骨性關節炎之組合物及方法 |
-
2019
- 2019-11-25 RS RS20230911A patent/RS64668B1/sr unknown
- 2019-11-25 JP JP2021529734A patent/JP7399502B2/ja active Active
- 2019-11-25 PL PL19805716.8T patent/PL3886857T3/pl unknown
- 2019-11-25 EP EP19805716.8A patent/EP3886857B1/en active Active
- 2019-11-25 MX MX2021006209A patent/MX2021006209A/es unknown
- 2019-11-25 DK DK19805716.8T patent/DK3886857T3/da active
- 2019-11-25 CN CN201980089991.6A patent/CN113347975B/zh active Active
- 2019-11-25 WO PCT/EP2019/082425 patent/WO2020109230A1/en not_active Ceased
- 2019-11-25 SI SI201930635T patent/SI3886857T1/sl unknown
- 2019-11-25 MD MDE20210946T patent/MD3886857T2/ro unknown
- 2019-11-25 MA MA54276A patent/MA54276B1/fr unknown
- 2019-11-25 ES ES19805716T patent/ES2961390T3/es active Active
- 2019-11-25 BR BR112021009980-8A patent/BR112021009980A2/pt unknown
- 2019-11-25 FI FIEP19805716.8T patent/FI3886857T3/fi active
- 2019-11-25 AU AU2019386235A patent/AU2019386235B2/en active Active
- 2019-11-25 US US17/296,703 patent/US12539296B2/en active Active
- 2019-11-25 HU HUE19805716A patent/HUE063579T2/hu unknown
- 2019-11-25 PT PT198057168T patent/PT3886857T/pt unknown
- 2019-11-25 CA CA3120920A patent/CA3120920C/en active Active
- 2019-11-25 HR HRP20231283TT patent/HRP20231283T1/hr unknown
- 2019-11-25 MY MYPI2021002897A patent/MY203365A/en unknown
- 2019-11-26 TW TW108142961A patent/TWI850283B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3886857T (pt) | 2023-10-25 |
| AU2019386235B2 (en) | 2024-11-21 |
| TWI850283B (zh) | 2024-08-01 |
| CA3120920C (en) | 2024-01-02 |
| EP3886857A1 (en) | 2021-10-06 |
| SI3886857T1 (sl) | 2023-12-29 |
| MD3886857T2 (ro) | 2023-12-31 |
| HRP20231283T1 (hr) | 2024-02-02 |
| EP3886857B1 (en) | 2023-07-26 |
| US20220047570A1 (en) | 2022-02-17 |
| JP7399502B2 (ja) | 2023-12-18 |
| MA54276A (fr) | 2021-10-06 |
| MA54276B1 (fr) | 2023-11-30 |
| JP2022508236A (ja) | 2022-01-19 |
| HUE063579T2 (hu) | 2024-01-28 |
| PL3886857T3 (pl) | 2024-01-15 |
| MX2021006209A (es) | 2021-08-11 |
| CA3120920A1 (en) | 2020-06-04 |
| BR112021009980A2 (pt) | 2021-08-17 |
| FI3886857T3 (fi) | 2023-10-20 |
| AU2019386235A1 (en) | 2021-07-01 |
| CN113347975A (zh) | 2021-09-03 |
| CN113347975B (zh) | 2024-08-30 |
| MY203365A (en) | 2024-06-26 |
| DK3886857T3 (da) | 2023-10-09 |
| TW202038954A (zh) | 2020-11-01 |
| US12539296B2 (en) | 2026-02-03 |
| RS64668B1 (sr) | 2023-11-30 |
| WO2020109230A1 (en) | 2020-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2225926T3 (es) | Composiciones para potenciar la penetracion de farmacos usando promotores de permeacion. | |
| ES2245511T3 (es) | Lociones de vitamina d3 activa en forma de emulsion. | |
| ES2627405T3 (es) | Composiciones que comprenden brimonidina para el tratamiento del eritema | |
| ES2741146T3 (es) | Formulaciones farmacéuticas de nitrio y sus usos | |
| KR20080105864A (ko) | 리마프로스트를 함유하는 경추증의 치료 및/또는 증상 진전억제제 | |
| US20230302008A1 (en) | Methods of administering intravenous meloxicam in a bolus dose | |
| HUP0401854A2 (hu) | COX-2 inhibitorokat és aszpirint tartalmazó kombinációk | |
| CA3120920C (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| RU2101014C1 (ru) | Анальгезирующее, противовоспалительное, жаропонижающее лекарственное средство и способ его получения | |
| JP2022505572A (ja) | 術前および他の薬物との組み合わせでのメロキシカムの静脈内投与方法 | |
| RU2809024C2 (ru) | Монтелукаст для лечения эрозивного остеоартрита кистей рук | |
| US20150010627A1 (en) | New pharmaceutical compositions of flurbiprofen and glucosamin | |
| HK40054679A (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| HK40054679B (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| JP3150642B2 (ja) | 新規な抗痙攣性及び抗炎症性組成物並びにそれらの製造方法 | |
| KR20230018481A (ko) | 질병의 치료를 위한 2-(다이에틸아미노)에틸 2-(4-아이소부틸페닐)프로피오네이트의 국소 투여 | |
| CN106714803A (zh) | 眼用混悬液制剂 | |
| JP2008156232A (ja) | リマプロストを含有してなる頚椎症の治療および／または症状進展抑制剤 | |
| NZ540415A (en) | Use of levocetirizine for the treatment of persistent allergic rhinitis | |
| KR20060123329A (ko) | 월경 곤란증의 예방 및/또는 치료제 | |
| UA122476C2 (uk) | М'яка лікарська форма для місцевого лікування поверхневих інфантильних гемангіом | |
| BR112012030704B1 (pt) | Composição farmacêutica de cocristais e processo para sua produção | |
| JPWO2005058879A1 (ja) | 滲出性中耳炎の予防および／または治療剤 | |
| PT85135B (pt) | Processo para a preparacao de misturas de diflunisal e trometamina | |
| Mounnissamy | International Journal Research Publication Analysis |